A Phase 3 interventional study of ARGX-113 and Placebo in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 66 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-08.
Sponsored by argenx · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 2nd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:
argenx · Sites in United States, Belgium, Germany and 5 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 65+
argenx · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 18+
Clinique Neuro-Outaouais · Sites in Canada
Ages 18–80
By country, each count listing its studies:
efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 12 · Phase 4 4
First in 2016; this study’s year is marked. 1 started in 2018.
This study's enrollment of 167 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 55 across the 20 interventional studies. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 8 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
18 studies in Myasthenia Gravis by argenx: 9 open now, 12 under way, 5 of them phase 3. Of 6 finished, 6 (100%) have results posted.
Among the 18 studies in Myasthenia Gravis by argenx, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 2nd registered.
argenx’s Myasthenia Gravis studies by the year they started, since 2016.
7 of the studies testing efgartigimod alfa in Myasthenia Gravis that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06765161Phase 3Clinique Neuro-OutaouaisEfgartigimod in IVIG Dependent Myasthenia Gravis Patients | 2027-01-06 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT07231523Phase 3Shanghai Zhongshan HospitalEFG vs IVIG in TAMG | 2027-06-01 |
| NCT06392386Phase 3argenxA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | 2027-09 |
| NCT06221501Shanghai Zhongshan HospitalPerioperative Efgartigimod for Thymoma and Myasthenia Gravis | 2026-12-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among argenx’s 18 in Myasthenia Gravis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other, more specific inclusion criteria are defined in the protocol
Exclusion Criteria:
Patients with known seropositivity or who test positive for an active viral infection at Screening with:
Other, more specific exclusion criteria are further defined in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ARGX-113
Biological: Placebo
Intravenous administration of ARGX-113
Also known as: efgartigimod
Intravenous administration of placebo
Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 \[C1B\]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.
Time frame: Baseline up to Day 63 (end of TC1)
Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population
The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.
Time frame: Baseline up to Day 63 (end of TC1)
Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population
The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point.
Time frame: Baseline up to Day 63 (end of TC1)
Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population
An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB).
Time frame: Baseline up to Day 126
Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population
Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a \<2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with \>50% of the total score attributable to nonocular symptoms.
Time frame: Week 4 up to Day 182 (end of study [EoS])
Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population
A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1).
Time frame: Baseline up to Day 63 (end of TC1)
Study was conducted in generalized myasthenia gravis (gMG) patients at 56 sites worldwide. Patients were randomized 1:1 within each stratum (Japanese/non-Japanese, acetylcholine receptor-antibody \[AChR-Ab\] status and standard of care \[SoC; ie, concomitant gMG treatment\]) to receive ARGX-113 intravenous (IV) 10 milligrams/kilogram (mg/kg) or placebo, in addition to SoC. Patients completing the study were eligible to roll over into a follow-up study ARGX-113-1705.
| Milestone | ARGX-113 | Placebo |
|---|---|---|
| Started | 84 | 83 |
| Completed | 80 | 76 |
| Not completed | 4 | 7 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Rescue therapy needed | 0 | 1 |
The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 \[C1B\]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.
| percentage of patients | ARGX-113 | Placebo |
|---|---|---|
| Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population | 67.7 | 29.7 |
The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.
| percentage of patients | ARGX-113 | Placebo |
|---|---|---|
| Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population | 63.1 | 14.1 |
The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point.
| percentage of patients | ARGX-113 | Placebo |
|---|---|---|
| Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population | 67.9 | 37.3 |
An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB).
| percentage of time | ARGX-113 | Placebo |
|---|---|---|
| Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population | 48.714 ± 6.163 | 26.649 ± 6.316 |
Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a \<2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with \>50% of the total score attributable to nonocular symptoms.
| days | ARGX-113 | Placebo |
|---|---|---|
| Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population | 35.0 (29.0 to 43.0) | 8.0 (1.0 to 30.0) |
A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1).
| percentage of patients | ARGX-113 | Placebo |
|---|---|---|
| Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population | 56.9 | 25.0 |
Collected over Treatment-emergent adverse events were monitored from first administration of IMP on Day 1 until the EoS (up to a maximum of approximately 182 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARGX-113 | 0/84 (0%) | 4/84 (4.8%) | 49/84 (58.3%) |
| Placebo | 0/83 (0%) | 7/83 (8.4%) | 48/83 (57.8%) |
| Event | ARGX-113 | Placebo |
|---|---|---|
| Myasthenia gravisNervous system disorders | 1/84 | 2/83 |
| Atrial fibrillationCardiac disorders | 0/84 | 1/83 |
| Myocardial ischaemiaCardiac disorders | 0/84 | 1/83 |
| Therapeutic product ineffectiveGeneral disorders | 0/84 | 1/83 |
| Upper respiratory tract infectionInfections and infestations | 0/84 | 1/83 |
| Procedural painInjury, poisoning and procedural complications | 0/84 | 1/83 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/84 | 1/83 |
| Spinal ligament ossificationMusculoskeletal and connective tissue disorders | 0/84 | 1/83 |
| Myasthenia gravis crisisNervous system disorders | 0/84 | 1/83 |
| ThrombocytosisBlood and lymphatic system disorders | 1/84 | 0/83 |
| Event | ARGX-113 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 24/84 | 23/83 |
| NasopharyngitisInfections and infestations | 10/84 | 15/83 |
| DiarrhoeaGastrointestinal disorders | 6/84 | 9/83 |
| NauseaGastrointestinal disorders | 7/84 | 9/83 |
| Upper respiratory tract infectionInfections and infestations | 9/84 | 4/83 |
| Urinary tract infectionInfections and infestations | 8/84 | 4/83 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/84 | 7/83 |
| HypertensionVascular disorders | 3/84 | 6/83 |
| DizzinessNervous system disorders | 3/84 | 5/83 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/84 | 5/83 |
All patients in the randomized population who received at least a partial dose of investigational medicinal product (IMP) were included in the baseline analysis.
| Age, Continuous(years) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Mean | 45.9 ± 14.41 | 48.2 ± 14.97 | 47.0 ± 14.69 |
| Age, Customized(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| 18 - <65 years | 73 | 69 | 142 |
| >= 65 years | 11 | 14 | 25 |
| Sex: Female, Male(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Female | 63 | 55 | 118 |
| Male | 21 | 28 | 49 |
| Race (NIH/OMB)(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 9 | 7 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 69 | 72 | 141 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Japanese | 8 | 7 | 15 |
| Hispanic or Latino | 7 | 2 | 9 |
| Not Hispanic or Latino | 69 | 73 | 142 |
| Not Reported | 0 | 1 | 1 |
| Concomitant gMG treatment(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Nonsteroidal Immunosuppressive Drugs (NSIDs) | 51 | 51 | 102 |
| No NSIDs | 33 | 32 | 65 |
| AChR-Ab status(Participants) | ARGX-113 | Placebo | Total |
|---|---|---|---|
| Positive | 65 | 64 | 129 |
| Negative | 19 | 19 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Apr 2020, 19 months.
Results were first posted in Feb 2022, 1 year 10 months after primary completion. A results delay was requested in Mar 2021.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 19 months is below that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa